Multicyclic Compounds for Proline Transporter Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of the Na+-dependent proline transporter's role in neurotransmitter signaling is limited, and its inhibition for pain treatment lacks experimental support, while its potential role in cognitive functions remains unexplored.
Innovation Solution
Development of multicyclic compounds that specifically inhibit the proline transporter without affecting dopamine or glycine transporters, potentially improving cognitive performance and treating cognitive disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to inhibit the proline transporter, then cognitive function improvement is achieved, but specificity against other transporters (dopamine, glycine) must be maintained
Solution Approach 1:
The patent applies local quality by introducing specific heterocyclic substituents at particular positions on the core molecular structure. The heterocycle is positioned at a specific location to interact with the proline transporter binding site, while other parts of the molecule maintain interactions necessary for selectivity against dopamine and glycine transporters. This localized modification achieves the desired specificity without requiring complete redesign of the entire molecular structure.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters such as heterocycle type, substitution patterns, and molecular rigidity to optimize the balance between proline transporter inhibition potency and selectivity. By adjusting these molecular parameters, the compounds achieve high specificity for the proline transporter while maintaining appropriate binding characteristics for other transporters, resolving the contradiction between reliability and complexity.
2Reliability
If the proline transporter is inhibited to treat cognitive disorders, then therapeutic benefit is achieved, but off-target effects on other neurotransmitter systems must be avoided
Solution Approach 1:
The patent uses the multicyclic compound structure as an intermediary that selectively mediates interaction with the proline transporter while avoiding harmful interactions with dopamine and glycine transporters. The specific molecular architecture acts as a mediator that translates the therapeutic intent into selective proline transporter inhibition, preventing off-target effects through its designed structural features that match the proline transporter binding pocket geometry and chemistry.
3Reliability
If multicyclic compounds with heterocyclic substituents are synthesized, then proline transporter inhibition is achieved, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the multicyclic compound into modular components: a core structure and separable heterocyclic substituent units. This segmentation allows the heterocycles to be synthesized independently and then attached to the core structure through standardized coupling reactions, reducing overall synthesis complexity while maintaining the potency required for effective proline transporter inhibition.
Data Source
AI summary
This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use in, for example, the treatment of cognitive disorders.